

Phase III Biologics Company Looking to Raise Capital for Plasma-derived Therapeutics

Looking for an equity raise of \$60 Million for Series A Funding

+ Private-Equity owned, Phase III plasma-derived therapeutic company is ready to build the commercial facility with One Million Liter annual capacity, in Dallas Texas, with \$1.5 Billion in future annual revenue.

+ C-Suite Leadership Team each with 25 years of industry experience in Hemophilia, Blood Plasma and Biologic Therapeutics, leading a team of 30 scientists over the last 10 years.

+ This Biologics Company is focused on the development, manufacturing and commercialization of life-saving, plasma-derived therapeutics using high yield proprietary technology.

+ Successful completion of Adult and Pediatric Phase III Intravenous Immunoglobulin (IVIG) Clinical Trial in Primary Immune Deficiency Disease (PIDD). FDA confirmation, no clinical trial needed for second commercial product Albumin.

+ \$12 Billion US market opportunity, consistent high-volume growth, underserved market for protein IVIG.

+ 80% of first year production capacity pre-sold prior to construction of commercial facility.

+ 70% of raw material blood plasma supply chain for first 3 years of operation is already secured.

+ Please request the CIM after Fully Executed NDA.

